Related Experiment Videos
Bupivacaine kinetics during hyperthermia in rats
B Bruguerolle1, X Roucoules, L Attolini
1Medical Pharmacology Laboratory, Faculty of Medicine of Marseille, France.
Summary
Hyperthermia significantly reduces bupivacaine clearance in rats, affecting its pharmacokinetic behavior. This finding highlights potential clinical implications for managing patients with elevated body temperatures during bupivacaine administration.
Area of Science:
- Pharmacology
- Toxicology
- Physiology
Background:
- Bupivacaine is a commonly used local anesthetic.
- Hyperthermia can alter drug metabolism and disposition.
- Understanding bupivacaine pharmacokinetics during hyperthermia is crucial for safe clinical use.
Purpose of the Study:
- To investigate the impact of induced hyperthermia on the pharmacokinetic profile of bupivacaine in a rat model.
- To quantify changes in bupivacaine clearance and metabolite formation under hyperthermic conditions.
Main Methods:
- Wistar rats were divided into normothermic and hyperthermia groups.
- Bupivacaine was administered intraperitoneally at a dose of 20 mg/kg.
- Blood samples were collected at various time points for analysis of bupivacaine and its metabolite, 2,6-desbutylbupivacaine (PPX).
- Gas liquid chromatography was used for drug assay.
- Pharmacokinetic parameters (Cmax, Tmax, t1/2, Cl, Vd, AUC) were calculated using a two-compartment open model.
Main Results:
- A significant decrease in bupivacaine clearance was observed in hyperthermic rats compared to normothermic controls (4.59 vs. 5.85 ml/hr/kg, P < 0.05).
- The Tmax of the metabolite PPX was significantly shorter in hyperthermic rats (0.15 vs. 0.24 hr, P < 0.05).
Conclusions:
- Induced hyperthermia leads to reduced bupivacaine clearance in rats.
- These pharmacokinetic alterations may have significant clinical implications for anesthesia and pain management in hyperthermic patients.